Valneva (NASDAQ:VALN) Shares Gap Down – Time to Sell?

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN) gapped down before the market opened on Monday. The stock had previously closed at $5.71, but opened at $5.35. Valneva shares last traded at $5.3950, with a volume of 176 shares trading hands.

Analyst Upgrades and Downgrades

VALN has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Valneva in a research report on Monday, September 14th. TD Cowen began coverage on Valneva in a research report on Tuesday, August 11th. They set a “buy” rating and a $12.00 target price on the stock. One investment analyst has rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Valneva currently has an average rating of “Reduce” and an average target price of $9.30.

Valneva Stock Down 2.5%

The company has a debt-to-equity ratio of 2.04, a quick ratio of 1.69 and a current ratio of 2.16. The firm has a market capitalization of $504.44 million, a P/E ratio of -2.53 and a beta of 1.37. The business’s fifty day moving average price is $6.18 and its two-hundred day moving average price is $6.87.

Valneva (NASDAQ:VALN) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.21). Valneva had a negative net margin of 110.33% and a negative return on equity of 153.20%. The firm had revenue of $39.37 million for the quarter, compared to analysts’ expectations of $44.17 million. Equities analysts expect that Valneva SE Sponsored ADR will post -1.27 earnings per share for the current fiscal year.

About Valneva

Valneva SE is a specialty vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases with significant unmet medical needs. The company combines vaccine research and development with in-house manufacturing and commercial operations serving public health agencies, travel medicine providers and private healthcare markets.

Valneva’s marketed products include IXIARO and JESPECT for the prevention of Japanese encephalitis, and DUKORAL, an oral vaccine used to help prevent cholera and, in some markets, enterotoxigenic Escherichia coli-related travelers’ diarrhea.